Optimal management of diabetes is essential to avoid chronic complications. 4 Maturity-onset diabetes of the young (MODY) is the most common type of monogenic diabetes. It constitutes a group of early-onset autosomal dominant forms of diabetes that together account for up to 2% of all HbA 1c was measured by high-performance liquid chromatography (Bio-Rad, Hercules, California, United States). Fasting glucose levels were determined with the oxidase method. C-peptide levels were determined by an enzyme immunoassay. A diagnosis of diabetic microvascular complications-retinopathy and nephropathy-was established as described previously. 9 Genomic DNA was extracted from peripheral blood with a Maxwell Instrument (Promega, Madison, Wisconsin, United States). Libraries were prepared according to an established protocol. 7, 10 For target enrichment, we used a custom Agilent Sure Select exon-capture assay with baits designed to target exons and splice sites of 28 genes known to be associated with monogenic forms of diabetes such as MODY, neonatal diabetes, and lipodystrophy. Target genes were as follows: ABCC8, BLK, CEL, EIF2AK3, FOXP3, GATA4, GATA6, GCK, GLIS3, HNF1A, HNF1B, HNF4A, IER3IP1, INS, KCNJ11, KLF11, LMNA, NEUROD1, NEUROG3, PAX4, PDX1, PPARG, PTF1A, RFX6, SLC19A2, SLC2A2, WFS1, and ZFP57. The final captured library was sequenced on the MiSeq platform (Illumina, San Diego, California, United States) using 75bp paired--end reads.
Data were processed as follows: reads were aligned to the 1000 Genomes Project reference genome (GRCh37-derived reference sequence) using the BWA-MEM 0.7.5a algorithm. Duplicates were removed using SAMTools 0.1.19.
11 Realignment across indels and base quality recalibration were performed with GATK 3.1. 12 Variants were called using a Unified Genotyper and filtered using recommended hard filtering parameters (GATK Best Practices v4).
13,14 The SnpEff tool was used for variant annotation. 15 Variants were annotated with chromosome location, genomic coordinate, reference and variant nucleotide, absolute number and percentage of reads containing variant nucleotide, reference and variant amino acid, coding frame, gene name, and overlap with a known single nucleotide polymorphism (SNP) from dbSNP 135. 16 The final variant filtering and prioritization was performed with GEMINI based on alternative allele frequency lower than 0.001 in the European American population in the Exome Sequencing Project and lower than 0.3 in the studied cohort, which was a lower threshold than the one typically used (0.2), owing to the small size of the group and the fact that there was more than 1 examined patient per family.
17 Only variants covered by 8 or more reads and with genotype quality over 19 were included in the final analysis. Variant impacts were divided into severity classes according to GEMI-NI mapping (https://gemini.readthedocs.org). Next, the results were sent for confirmation by the Sanger method. Direct sequencing was performed using labeled dideoxy-terminated nucleotides and 1 oligonucleotide primer. A computer analysis of the chromatograms obtained was conducted using the DNA Sequencing Analysis Software (Applied Biosystems, Foster City, California, diabetic cases. Thus, we estimate that in Poland the number of patients with MODY is around 20 000 to 30 000. Most cases are usually diagnosed before the age of 25 years; however, many patients are identified in the fourth or fifth decade of life or even later. 1,2 Some patients with MODY may present with obesity, although it is not a typical feature. Consequently, the overlap of clinical characteristics between MODY, type 1 diabetes, and type 2 diabetes represents a challenge for differential diagnosis. 3 Moreover, the clinical phenotype in individuals with MODY may vary within the same pedigree. 1 So far around a dozen genes have been reported to be responsible for MODY. Genetic testing has frequently relied on phenotype-guided screening for the most common MODY genes such as HNF1A and GCK. Therefore, molecular screening in many countries, particularly in those where genetic testing is not reimbursed by a national health care system, has been limited only to the 2 or 3 most common MODY genes. Owing to limitations both in funding and access to genetic diagnostic facilities, patients who test negative for mutations in these genes have been underdiagnosed and consequently have often received inappropriate therapy. 5 With the advent of high--throughput next-generation sequencing (NGS) technology, there has been an improvement in screening strategies enabling a simultaneous analysis of a panel of genes at a comparable cost to testing a few genes by Sanger sequencing. 6, 7 In this study, we aimed to assess the utility of NGS for detecting mutations in a set of known monogenic diabetes genes, using a cohort of Polish patients with negative results for HNF1A--MODY or GCK-MODY in Sanger sequencing screening.
PATIENTs ANd mEThOds A contact database of MODY families is maintained at the Department of Metabolic Diseases, Kraków, Poland, based on the following criteria: 1) autosomal dominant inheritance pattern of diabetes mellitus; 2) presence of the disease in at least 3 consecutive generations; 3) at least 2 diabetic family members diagnosed at the age of 30 years or earlier and treated for at least 2 years with diet, oral medication, or insulin at a dose lower than 0.5 U/kg. Details of the ascertainment protocol were described in previous papers. 8, 9 The current study group consisted of 54 probands who had been screened for mutations in the HNF1A and GCK genes by Sanger sequencing and showed negative results. Additionally, 9 positive controls in whom mutations in the GCK or HNF1A genes were previously identified by Sanger sequencing were included. The study was performed according to the Declaration of Helsinki, and was approved by the Bioethical Committee of the Jagiellonian University.
We performed basic clinical laboratory analyses, including the measurement of hemoglobin A 1c (HbA 1c ), fasting glucose, and C-peptide levels.
First, we confirmed the segregation of 11 mutations detected in the GCK gene. Among them, there were 4 known amino-acid substitutions (Met235Val, Leu164Pro, Leu315His, and Gly175Arg) previously missed in Sanger sequencing and 5 earlier reported sequence differences (Gly318Arg, Gly261Arg, Cys220Term, Phe438Ser, and Val302Leu) identified in 7 patients screened earlier for the HNF1A mutation. At the time of the examination, 6 of these 11 probands were on diet, 1 was treated with insulin, and 4 were on oral drugs.
The mutation identified in the HNF1A (Ala532Thr) gene was previously described. The proband from this family was earlier diagnosed with gestational diabetes at the age of 37 years along with a relatively mild manifestation of hyperglycemia, which was treated only with diet. She was screened for the GCK mutation at the age of 41 years.
We also positively verified the segregation of the NEUROD1 Arg103Pro mutation. The pedigree, consisting of 17 family members and 11 mutation carriers, has been reported in a separate paper (under review).
United States). The Sequencer software version 4.1.4 and bioinformatics tools available online at http://genome.ucsc.edu were used for the submission and comparative analysis.
REsuLTs Sequencing results were generated for all 54 patients and 9 positive controls with a previously identified HNF1A or GCK gene mutation. All previously identified sequence differences (Met57Thr, Leu315His, and Gly318Arg [in 2 patients] in the GCK gene and Gln109* [in 2 patients], Arg238Thr [in 2 patients], and Gly292Argfs*25 in the HNF1A gene) were found by NGS in the control group. High (n = 3) or moderate (n = 76) impact genetic changes in 16 genes were found in the study group.
So far, 21 mutations in 18 patients have been confirmed using the Sanger method (TAbLE 1) . None of the sequence differences selected for Sanger verification was a false positive finding. Among them, there were 11 mutations in the GCK gene, 1 in HNF1A, 5 in HNF4A, 1 in NEUROD1, 1 in HNF1B, 1 in GLIS3, and 1 in PTF1A (TAbLE 1) . The segregation of these variants with diabetes has been confirmed in 14 pedigrees. In the current study, we performed the NGS screening to detect mutations in a set of known monogenic diabetes genes using a cohort of Polish patients with previous negative Sanger sequencing screening results for HNF1A-MODY or GCK-MODY. To our knowledge, this study is the first of this type to investigate the clinical application of NGS in the diagnosis of diabetes in Poland.
Since an accurate etiological diagnosis of monogenic forms of diabetes has been proved to lead to a marked improvement both in patient care and family counseling, the use of cost-efficient, fast, and high-throughput methods for an accurate DNA sequencing is of major medical interest for contemporary diabetology. All mutations previously found by Sanger in our 9 positive controls were also confirmed by the NGS method, which demonstrated the diagnostic accuracy of the latter tool. Furthermore, 4 GCK mutations that had been previously missed by Sanger sequencing were subsequently identified by NGS in our study.
It has been reported that NGS is helpful in identifying variants that were earlier missed by traditional sequencing. 6 Our MODY database was established almost 20 years ago, 21 and over this period, our samples were screened in several collaborating laboratories in which quality control procedures and certification process have been rigorously introduced. Additionally, our screening with NGS resulted in improved diagnosis of MODY by detecting mutations in genes other The last mutation identified by NGS and verified by Sanger sequencing, and for which segregation has been confirmed, is the Gly42Arg substitution in the HNF4A gene in family M050 (FIGuRE 1) . Interestingly, the heterozygous mutation Thr376Ile in HNF1B was also identified by both methods in the proband of this family. This patient had been diagnosed with diabetes and added into our database at the age of 33 years. At the time of diagnosis in 2006, her body mass index was 23 kg/m 2 with no diabetic complications, and sulfonylurea treatment was introduced. The patient's DNA was scanned for HNF1A mutation with negative results. There were 3 more diabetic family members (a mother and 2 siblings) available for examination. Both siblings carried the HNF4A, but not the HNF1B, variant, whereas her mother carried both mutations (FIGuRE 1) . Clinical characteristics of the family members are provided in TAbLE 2. The Gly42Arg substitution is localized between the dimerization domain and DNAbiding domain of the polypeptide. The most likely functional mechanism of this variant is related to a modified charge for this part of the transcription factor: glycine belongs to neutral amino acids while arginine is basic.
18,19 This mutation and the consequent sequence alteration have been reported to cause diabetes.
17 The Thr376Ile variant is localized in a transactivation domain of the transcription factor HNF1B. 20 This variant has not been reported so far and its pathogenic role is uncertain. Interestingly, a polar amino acid is substituted by a hydrophobic one. Interestingly, we found more than 1 highly or moderately suspected variant of the MODY gene in some probands, such as the one from pedigree M050. This will be explored in future studies to better understand the range of phenotypes found in affected pedigrees, including the vast majority with only a single mutation confirmed previously as segregating with supposedly monogenic diabetes. The ongoing progress in sequencing has made it clear that the phenotypes associated with so called monogenic diseases can be due to a set of penetrant mutations in several causative genes. 26 This could be the case in family M050 as a pathogenic role of the Thr376Ile in the HNF1B gene cannot be excluded. It is nevertheless challenging to interpret NGS results to define which detected mutation is clinically responsible for diabetes and other potential accompanying abnormalities. We believe that the assessment of all known susceptibility genes for monogenic diabetes by NGS will bring an improved and less biased analysis of the causes of the disease in the near future. As the final outcome should benefit the patient and possibly his or her family, the obvious challenge is to detect all putatively deleterious mutations that may be present in the same pedigree.
Our study has a few limitations. First, its novelty is limited as there were some earlier reports on the use of NGS in monogenic diabetes. 6, 7, 26 Additionally, it should be considered as a pilot study that includes mutations in the most common MODY genes and their segregation in the families that were available for prompt examination and lacked the Sanger confirmation of some mutations detected by NGS. We are currently performing this verification together with NGS screening for the rest of probands from our cohort. Further research is also needed to explore the pedigrees of all index cases.
In conclusion, we demonstrated the feasibility of using NGS for monogenic diabetes screening in routine genetic testing of our MODY cohort in than HNF1A and GCK, which had previously been beyond our screening capabilities. 8 A similar study conducted in England, which used NGS-based genetic screening of a 29-gene panel implicated in monogenic diabetes, has also shown an increase of 17% in the detection of mutations. 7 In the same study, 6 of 14 newly identified mutations were in rare monogenic diabetes genes that have not been screened owing to the absence of characteristic features of their subtypes. It is noteworthy that the number of patients presenting with monogenic diabetes is currently underestimated. 7 Shields et al 22 reported that more than 80% of MODY cases were undiagnosed. The use of NGS methodology will likely reduce this estimate rapidly. It is expected that this will be associated by a reduction in the financial cost of sequencing. We estimate that the cost of mutation screening in the current set of genes for 1 sample in this study was similar or even lower than the price for 1 gene (consisting of approximately 10 exons) search by the Sanger method. Based on the results assessed by the simulated model, it is expected that generalized screening for monogenic diabetes will become more cost-effective with advances in sequencing technology.
23
While it is generally believed that findings from NGS should be confirmed by Sanger sequencing, this confirmation involves only specific exons with suspected sequence differences. Moreover, it is expected that NGS technology will become increasingly reliable with time. For example, the US Food and Drug Administration has already approved the MiSeq platform for cystic fibrosis mutation screening (http://www.illumina.com/ clinical/diagnostics/miseqdx-instrument.html). There are also reports on other monogenic diseases, which show that targeted NGS sequencing is currently as reliable as the Sanger method.
24 In line with this, none of the variants selected by us for Sanger verification were false positive, unlike some earlier data generated by NGS, which contained such errors.
25 However, those previous data came from whole-genome sequencing research and included low-coverage data. Our research involved targeted sequencing in a relatively low number of genes with higher coverage. Additionally, we used a newer platform with high reliability. We also focused on the search for rare this pilot study. The screening should include patients with suspected MODY that had not been previously confirmed by Sanger-based screening.
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